Overweight, Obesity, and Late-Life Sarcopenia Among Men With Cardiovascular Disease, Israel
Related Experiment Video
Updated: Oct 24, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Miri Lutski1,2, Galit Weinstein3, David Tanne4,5
1The Israel Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Israel.
Insights
Obesity is linked to a higher risk of sarcopenia, the age-related loss of muscle mass and function, in men with cardiovascular disease. This suggests obesity may be a modifiable factor to consider in preventing sarcopenia.
Area of Science:
- Gerontology
- Cardiology
- Nutritional Science
Background:
- Sarcopenia, the age-related loss of muscle mass and function, is a growing concern in aging populations.
- The relationship between obesity and sarcopenia, particularly in individuals with cardiovascular disease, remains under-researched.
Purpose of the Study:
- To investigate the association between overweight, obesity, and sarcopenia in community-dwelling men with cardiovascular disease.
- To determine if obesity is a risk factor for developing sarcopenia in this specific patient group.
Main Methods:
- A subset of 337 men from the Bezafibrate Infarction Prevention trial underwent sarcopenia evaluation.
- A multinomial logistic model was used to analyze the odds of probable sarcopenia and sarcopenia based on body mass index (BMI).
Main Results:
- Sarcopenia was prevalent in 54.3% of participants with obesity (BMI ≥30.0) and 37.0% of overweight participants (25.0 ≤ BMI ≤29.9).
- Overweight and obesity (BMI ≥25.0) were associated with significantly higher odds of probable sarcopenia (OR=3.27) and sarcopenia (OR=5.31) compared to normal weight (BMI <25.0).
Conclusions:
- A positive association exists between obesity and late-life sarcopenia in men with cardiovascular disease.
- Obesity may be an important, modifiable risk factor for sarcopenia in this population.
Introduction:
Little is known about the association between obesity and sarcopenia - age-related loss of muscle mass and function - among patients with cardiovascular disease. We investigated the association between overweight, obesity, and sarcopenia among community-dwelling men in Israel with cardiovascular disease.
Methods:
A subset of 337 men (mean age at baseline 56.7 [SD, 6.5]) who previously (1990-1997) participated in the Bezafibrate Infarction Prevention trial underwent a neurovascular evaluation as part of the Bezafibrate Infarction Prevention Neurocognitive Study 15.0 (SD, 3.0) years after baseline and a sarcopenia evaluation 19.9 (SD, 1.0) years after baseline. We applied a multinomial logistic model to estimate odds ratios and 95% CIs for 3 categories of sarcopenia: no evidence of sarcopenia (ie, robust), probable sarcopenia, and sarcopenia.
Results:
We found sarcopenia among 54.3% of participants with obesity (body mass index [BMI, in kg/m2] ≥30.0), 37.0% of participants who were overweight (25.0 ≤ BMI ≤29.9), and 24.8% of participants with normal weight (BMI 18.5 to 24.9). In a comparison of BMI ≥25.0 and BMI <25.0, adjusting for covariates, the odds ratio of having probable sarcopenia was 3.27 (95% CI, 1.68-6.36) and having sarcopenia was 5.31 (95% CI, 2.50-11.27).
Conclusion:
We found a positive association between obesity and late-life sarcopenia and suggest that obesity might be an important modifiable risk factor related to sarcopenia among men with cardiovascular disease.
Related Concept Videos
The Effect of Aging on Tissues
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Obesity
Coronary Artery Disease I: Introduction
Coronary Artery Disease III: Clinical Manifestations
Cardiomyopathy III: Hypertrophic Cardiomyopathy

